Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Roberto Pili
- Target Recruit Count
- 72
- Registration Number
- NCT03024437
- Locations
- ๐บ๐ธ
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธIndiana University Health Hospital, Indianapolis, Indiana, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT03023423
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
- Conditions
- Interventions
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 759
- Registration Number
- NCT03016312
- Locations
- ๐บ๐ธ
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
๐บ๐ธCity of Hope Medical Grp Inc., Duarte, California, United States
๐บ๐ธUniversity of California San Diego, La Jolla, California, United States
Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Liza Villaruz, MD
- Target Recruit Count
- 28
- Registration Number
- NCT03014648
- Locations
- ๐บ๐ธ
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธAdventHealth Orlando, Orlando, Florida, United States
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT02997228
- Locations
- ๐บ๐ธ
Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States
๐บ๐ธLaura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
๐บ๐ธUniversity of Rochester, Rochester, New York, United States
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 60
- Registration Number
- NCT02994576
- Locations
- ๐ซ๐ท
Gustave Roussy, Villejuif, Val De Marne, France
๐ซ๐ทCentre Hospitalier de Chauny, Chauny, France
๐ซ๐ทCentre Marie Lannelongue, Le Plessis Robinson, France
A Phase II Study of Atezolizumab in Combination with Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT02989584
- Locations
- ๐บ๐ธ
Ohio State University, Columbus, Ohio, United States
๐บ๐ธMemorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
๐บ๐ธHartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 46
- Registration Number
- NCT02982694
- Locations
- ๐ฎ๐น
Ospedale Niguarda CA Granda, Milano, Italy
๐ฎ๐นSecond University of Naples, Naples, Italy
๐ช๐ธInstitut Catalร d'Oncologia, Barcelona, Spain
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT02951767
- Locations
- ๐บ๐ธ
USC Norris Cancer Center, Los Angeles, California, United States
๐บ๐ธKaiser Permanente; Oncology Clinical Trials, Vallejo, California, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 33
- Registration Number
- NCT02935361
- Locations
- ๐บ๐ธ
Temple University Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Maryland Medical Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.